Literature DB >> 27908448

Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis.

Alexander A Navarini1, Petr Hruz2, Christoph T Berger3, Tie Zheng Hou4, Charlotte Schwab5, Annemarie Gabrysch5, Rebecca Higgins1, Natalie Frede5, Barbara-Christina Padberg Sgier6, Olle Kämpe7, Anne-Valérie Burgener8, Florian Marquardsen9, Fabian Baldin9, Marc Bigler3, Anne Kistner3, Annaise Jauch9, Olivier Bignucolo10, Benedikt Meyer9, Fabian Meienberg11, Matthias Mehling12, Lukas T Jeker13, Ingmar Heijnen14, Thomas D Daikeler15, Jan-Olaf Gebbers6, Bodo Grimbacher5, David M Sansom4, Raphael Jeker16, Christoph Hess8, Mike Recher17.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27908448     DOI: 10.1016/j.jaci.2016.08.042

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  13 in total

Review 1.  The Treatment of Inflammatory Bowel Disease in Patients with Selected Primary Immunodeficiencies.

Authors:  Dror S Shouval; Matthew Kowalik; Scott B Snapper
Journal:  J Clin Immunol       Date:  2018-06-29       Impact factor: 8.317

Review 2.  Targeted strategies directed at the molecular defect: Toward precision medicine for select primary immunodeficiency disorders.

Authors:  Luigi D Notarangelo; Thomas A Fleisher
Journal:  J Allergy Clin Immunol       Date:  2017-03       Impact factor: 10.793

3.  Vedolizumab therapy in common variable immune deficiency associated enteropathy: A case series.

Authors:  Travis Sifers; Robert Hirten; Saurabh Mehandru; Huaibin Mabel Ko; Jean-Frederic Colombel; Charlotte Cunningham-Rundles
Journal:  Clin Immunol       Date:  2020-02-11       Impact factor: 3.969

Review 4.  Targeted Therapy with Biologicals and Small Molecules in Primary Immunodeficiencies.

Authors:  Ottavia Maria Delmonte; Luigi Daniele Notarangelo
Journal:  Med Princ Pract       Date:  2019-10-10       Impact factor: 1.927

Review 5.  Linking Genetic Diagnosis to Therapeutic Approach in Very Early Onset Inflammatory Bowel Disease: Pharmacologic Considerations.

Authors:  Anne E Levine; Hengqi B Zheng; David L Suskind
Journal:  Paediatr Drugs       Date:  2022-04-25       Impact factor: 3.022

Review 6.  Inflammatory Manifestations of Systemic Diseases in the Central Nervous System.

Authors:  David A Lapides; Mark M McDonald
Journal:  Curr Treat Options Neurol       Date:  2020-07-29       Impact factor: 3.598

7.  Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects.

Authors:  Charlotte Schwab; Annemarie Gabrysch; Peter Olbrich; Virginia Patiño; Klaus Warnatz; Daniel Wolff; Akihiro Hoshino; Masao Kobayashi; Kohsuke Imai; Masatoshi Takagi; Ingunn Dybedal; Jamanda A Haddock; David M Sansom; Jose M Lucena; Maximilian Seidl; Annette Schmitt-Graeff; Veronika Reiser; Florian Emmerich; Natalie Frede; Alla Bulashevska; Ulrich Salzer; Desirée Schubert; Seiichi Hayakawa; Satoshi Okada; Maria Kanariou; Zeynep Yesim Kucuk; Hugo Chapdelaine; Lenka Petruzelkova; Zdenek Sumnik; Anna Sediva; Mary Slatter; Peter D Arkwright; Andrew Cant; Hanns-Martin Lorenz; Thomas Giese; Vassilios Lougaris; Alessandro Plebani; Christina Price; Kathleen E Sullivan; Michel Moutschen; Jiri Litzman; Tomas Freiberger; Frank L van de Veerdonk; Mike Recher; Michael H Albert; Fabian Hauck; Suranjith Seneviratne; Jana Pachlopnik Schmid; Antonios Kolios; Gary Unglik; Christian Klemann; Carsten Speckmann; Stephan Ehl; Alan Leichtner; Richard Blumberg; Andre Franke; Scott Snapper; Sebastian Zeissig; Charlotte Cunningham-Rundles; Lisa Giulino-Roth; Olivier Elemento; Gregor Dückers; Tim Niehues; Eva Fronkova; Veronika Kanderová; Craig D Platt; Janet Chou; Talal A Chatila; Raif Geha; Elizabeth McDermott; Su Bunn; Monika Kurzai; Ansgar Schulz; Laia Alsina; Ferran Casals; Angela Deyà-Martinez; Sophie Hambleton; Hirokazu Kanegane; Kjetil Taskén; Olaf Neth; Bodo Grimbacher
Journal:  J Allergy Clin Immunol       Date:  2018-05-04       Impact factor: 10.793

Review 8.  Immune deficiency and autoimmunity in patients with CTLA-4 (CD152) mutations.

Authors:  N Verma; S O Burns; L S K Walker; D M Sansom
Journal:  Clin Exp Immunol       Date:  2017-07-21       Impact factor: 4.330

9.  Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor-Induced Enteritis.

Authors:  Pietro Diana; Charoen Mankongpaisarnrung; Michael B Atkins; Jay C Zeck; Aline Charabaty
Journal:  ACG Case Rep J       Date:  2018-02-28

Review 10.  Bacille Calmette-Guerin Complications in Newly Described Primary Immunodeficiency Diseases: 2010-2017.

Authors:  Cristiane de Jesus Nunes-Santos; Sergio D Rosenzweig
Journal:  Front Immunol       Date:  2018-06-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.